Jeremy P Cheadle
Overview
Explore the profile of Jeremy P Cheadle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
2753
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wills C, Watts K, Houseman A, Maughan T, Fisher D, Al-Tassan N, et al.
Sci Rep
. 2025 Jan;
15(1):2423.
PMID: 39827162
The location of a patient's colorectal cancer (CRC) influences their outcome but inherited factors may also be involved. We studied 1899 patients with advanced CRC (514 had proximal colonic, 493...
2.
Chen Z, Guo X, Tao R, Huyghe J, Law P, Fernandez-Rozadilla C, et al.
Nat Commun
. 2024 Apr;
15(1):3557.
PMID: 38670944
Genome-wide association studies (GWAS) have identified more than 200 common genetic variants independently associated with colorectal cancer (CRC) risk, but the causal variants and target genes are mostly unknown. We...
3.
Wills C, Houseman A, Watts K, Maughan T, Fisher D, Houlston R, et al.
BJC Rep
. 2024 Apr;
1(1):2.
PMID: 38665548
Background: Genome, transcriptome and methylome-wide association studies have identified single-nucleotide polymorphisms (SNPs) or genes at 258 loci associated with colorectal cancer (CRC) risk. We studied the relationship between these and...
4.
Paller C, Tukachinsky H, Maertens A, Decker B, Sampson J, Cheadle J, et al.
JCO Precis Oncol
. 2024 Feb;
8:e2300251.
PMID: 38394468
Purpose: Biallelic germline pathogenic variants of the base excision repair (BER) pathway gene predispose to colorectal cancer (CRC) and other cancers. The possible association of heterozygous variants with broader cancer...
5.
Wills C, Watts K, Maughan T, Fisher D, Al-Tassan N, Houlston R, et al.
Genes Chromosomes Cancer
. 2023 Feb;
62(6):332-341.
PMID: 36790221
Background: Therapeutic agents that specifically target patients with RAS mutant colorectal cancer (CRC) are needed. We sought potential drug targets by relating genome-wide association study and survival data in patients...
6.
Watts K, Wills C, Madi A, Palles C, Maughan T, Kaplan R, et al.
Int J Cancer
. 2022 Apr;
151(6):957-966.
PMID: 35467766
Cancer patients treated with capecitabine and oxaliplatin (XELOX) often develop hand-foot syndrome (HFS) or palmar-plantar erythrodysesthesia. Genetic variation in ST6GAL1 is a risk factor for type-2 diabetes (T2D), a disease...
7.
Palles C, West H, Chew E, Galavotti S, Flensburg C, Grolleman J, et al.
Am J Hum Genet
. 2022 Apr;
109(5):953-960.
PMID: 35460607
We report an autosomal recessive, multi-organ tumor predisposition syndrome, caused by bi-allelic loss-of-function germline variants in the base excision repair (BER) gene MBD4. We identified five individuals with bi-allelic MBD4...
8.
West H, Coffey M, Wagner M, McLeod H, Colley J, Adams R, et al.
JCO Precis Oncol
. 2022 Feb;
2:1-18.
PMID: 35135151
Purpose: Oxaliplatin forms part of routine treatment of advanced colorectal cancer; however, it often causes severe peripheral neuropathy, resulting in treatment discontinuation. We sought to determine the molecular and cellular...
9.
Wills C, He Y, Summers M, Lin Y, Phipps A, Watts K, et al.
Eur J Cancer
. 2021 Nov;
159:247-258.
PMID: 34794066
Background: While genome-wide association studies (GWAS) have identified germline variants influencing the risk of developing colorectal cancer (CRC), there has been limited examination of the possible role of inherited variation...
10.
Watts K, Wills C, Madi A, Palles C, Maughan T, Kaplan R, et al.
Int J Cancer
. 2021 Jul;
149(9):1713-1722.
PMID: 34270794
Chemotherapies administered at normal therapeutic dosages can cause significant side-effects and may result in early treatment discontinuation. Inter-individual variation in toxicity highlights the need for biomarkers to personalise treatment. We...